CRISPR Therapeutics (CRSP) News Today → 4 Cryptos BETTER than Bitcoin (From True Market Insiders) (Ad) Free CRSP Stock Alerts $56.22 +0.55 (+0.99%) (As of 05/17/2024 08:53 PM ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative May 20 at 5:12 AM | marketbeat.comCharles Schwab Investment Management Inc. Acquires 15,085 Shares of CRISPR Therapeutics AG (NASDAQ:CRSP)Charles Schwab Investment Management Inc. lifted its stake in CRISPR Therapeutics AG (NASDAQ:CRSP - Free Report) by 2.4% during the 4th quarter, according to its most recent disclosure with the SEC. The institutional investor owned 653,023 shares of the company's stock after buying an additional 1May 19 at 6:10 AM | americanbankingnews.comCRISPR Therapeutics (NASDAQ:CRSP) Stock Price Down 0.3%May 18 at 2:03 PM | uk.finance.yahoo.comCRSP May 2024 39.000 putMay 17 at 8:34 PM | marketbeat.comCRISPR Therapeutics AG (NASDAQ:CRSP) Shares Sold by Nikko Asset Management Americas Inc.Nikko Asset Management Americas Inc. lowered its position in CRISPR Therapeutics AG (NASDAQ:CRSP - Free Report) by 2.8% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 3,369,762 shares of the company'sMay 17 at 2:49 PM | marketbeat.comCRISPR Therapeutics (NASDAQ:CRSP) Shares Down 0.3% CRISPR Therapeutics (NASDAQ:CRSP) Stock Price Down 0.3%May 17 at 9:30 AM | fool.comIs CRISPR Therapeutics Stock a Buy?May 17 at 2:08 AM | americanbankingnews.comCRISPR Therapeutics AG (NASDAQ:CRSP) Receives Average Recommendation of "Hold" from AnalystsMay 17 at 2:08 AM | marketbeat.comCRISPR Therapeutics AG (NASDAQ:CRSP) Receives Average Recommendation of "Hold" from BrokeragesCRISPR Therapeutics AG (NASDAQ:CRSP - Get Free Report) has earned a consensus rating of "Hold" from the seventeen ratings firms that are presently covering the stock, MarketBeat Ratings reports. Two equities research analysts have rated the stock with a sell recommendation, seven have given a holdMay 16, 2024 | marketbeat.comFarrow Financial Inc. Acquires Shares of 18,920 CRISPR Therapeutics AG (NASDAQ:CRSP)Farrow Financial Inc. bought a new stake in CRISPR Therapeutics AG (NASDAQ:CRSP - Free Report) during the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm bought 18,920 shares of the company's stock, valued at approximately $1,184,000. Several other hedgMay 16, 2024 | marketbeat.comCRISPR Therapeutics (NASDAQ:CRSP) Stock Price Down 2.7%CRISPR Therapeutics (NASDAQ:CRSP) Shares Down 2.7%May 16, 2024 | investorplace.com7 No-Brainer Stocks to Buy and Hold for the Next 20 Years: May 2024May 15, 2024 | marketbeat.comCRISPR Therapeutics (NASDAQ:CRSP) Stock Price Up 2.2%CRISPR Therapeutics (NASDAQ:CRSP) Stock Price Up 2.2%May 15, 2024 | seekingalpha.comCRISPR Therapeutics AG (CRSP) BofA Securities 2024 Health Care Conference (Transcript)May 15, 2024 | fool.comIs CRISPR Stock Going to $95? 1 Wall Street Analyst Thinks So.May 14, 2024 | marketbeat.comCRISPR Therapeutics (NASDAQ:CRSP) Stock Price Up 3.4%CRISPR Therapeutics (NASDAQ:CRSP) Stock Price Up 3.4%May 14, 2024 | fool.com2 Healthcare Stocks to Buy and Hold for Great Long-Term PotentialMay 13, 2024 | marketbeat.comCRISPR Therapeutics (NASDAQ:CRSP) Shares Up 11.3%CRISPR Therapeutics (NASDAQ:CRSP) Stock Price Up 11.3%May 13, 2024 | americanbankingnews.comOppenheimer Cuts CRISPR Therapeutics (NASDAQ:CRSP) Price Target to $95.00May 13, 2024 | americanbankingnews.comCRISPR Therapeutics (NASDAQ:CRSP) Earns Market Outperform Rating from JMP SecuritiesMay 13, 2024 | americanbankingnews.comCRISPR Therapeutics' (CRSP) Neutral Rating Reiterated at Cantor FitzgeraldMay 13, 2024 | americanbankingnews.comCRISPR Therapeutics (NASDAQ:CRSP) Given New $67.00 Price Target at BarclaysMay 13, 2024 | americanbankingnews.comCRISPR Therapeutics (NASDAQ:CRSP) Given New $65.00 Price Target at Wells Fargo & CompanyMay 13, 2024 | investorplace.comThe 3 Best Cathie Wood Stocks to Buy in May 2024May 13, 2024 | markets.businessinsider.comStifel Nicolaus Sticks to Their Hold Rating for Crispr Therapeutics AG (CRSP)May 13, 2024 | marketbeat.comSwiss National Bank Has $9.31 Million Stock Holdings in CRISPR Therapeutics AG (NASDAQ:CRSP)Swiss National Bank decreased its stake in CRISPR Therapeutics AG (NASDAQ:CRSP - Free Report) by 9.8% in the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 148,700 shares of the company's stock afteMay 13, 2024 | americanbankingnews.comCRISPR Therapeutics (NASDAQ:CRSP) Price Target Cut to $88.00 by Analysts at Needham & Company LLCMay 13, 2024 | americanbankingnews.comRobert W. Baird Boosts CRISPR Therapeutics (NASDAQ:CRSP) Price Target to $52.00May 13, 2024 | americanbankingnews.comBrokers Set Expectations for CRISPR Therapeutics AG's Q2 2024 Earnings (NASDAQ:CRSP)May 13, 2024 | americanbankingnews.comQ2 2024 Earnings Estimate for CRISPR Therapeutics AG Issued By Brookline Capital Management (NASDAQ:CRSP)May 12, 2024 | americanbankingnews.comFY2025 EPS Estimates for CRISPR Therapeutics AG Decreased by Analyst (NASDAQ:CRSP)May 11, 2024 | marketbeat.comReynders McVeigh Capital Management LLC Has $5.76 Million Holdings in CRISPR Therapeutics AG (NASDAQ:CRSP)Reynders McVeigh Capital Management LLC raised its position in CRISPR Therapeutics AG (NASDAQ:CRSP - Free Report) by 20.8% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 92,048 shares of the company's stock after purchasMay 11, 2024 | finance.yahoo.comBroker Revenue Forecasts For CRISPR Therapeutics AG (NASDAQ:CRSP) Are Surging HigherMay 11, 2024 | investorplace.comThe 3 Most Undervalued Biotech Stocks to Buy in May 2024May 11, 2024 | americanbankingnews.comCRISPR Therapeutics (NASDAQ:CRSP) Stock Price Down 2.1% After Analyst DowngradeMay 10, 2024 | finance.yahoo.comCRISPR Therapeutics AG Reports Q1 2024 Earnings: Misses Analyst Net Income ForecastMay 10, 2024 | marketbeat.comCRISPR Therapeutics (NASDAQ:CRSP) Price Target Cut to $95.00Oppenheimer decreased their price target on shares of CRISPR Therapeutics from $102.00 to $95.00 and set an "outperform" rating for the company in a research note on Friday.May 10, 2024 | marketbeat.comCRISPR Therapeutics (NASDAQ:CRSP) Trading Down 2.1% After Analyst DowngradeCRISPR Therapeutics (NASDAQ:CRSP) Stock Price Down 2.1% After Analyst DowngradeMay 10, 2024 | finance.yahoo.comWe're Interested To See How CRISPR Therapeutics (NASDAQ:CRSP) Uses Its Cash Hoard To GrowMay 10, 2024 | marketbeat.comFY2025 EPS Estimates for CRISPR Therapeutics AG Lowered by Analyst (NASDAQ:CRSP)CRISPR Therapeutics AG (NASDAQ:CRSP - Free Report) - Investment analysts at Brookline Capital Management cut their FY2025 earnings estimates for CRISPR Therapeutics in a research report issued on Wednesday, May 8th. Brookline Capital Management analyst L. Cann now expects that the company will poMay 10, 2024 | markets.businessinsider.comBuy Rating Affirmed for Crispr Therapeutics AG on Strong Pipeline and Financial HealthMay 10, 2024 | americanbankingnews.comCRISPR Therapeutics (NASDAQ:CRSP) Trading Down 1.7% on Disappointing EarningsMay 9, 2024 | marketbeat.comCRISPR Therapeutics (NASDAQ:CRSP) Receives Market Outperform Rating from JMP SecuritiesJMP Securities reaffirmed a "market outperform" rating and set a $86.00 price objective on shares of CRISPR Therapeutics in a report on Thursday.May 9, 2024 | marketbeat.comCRISPR Therapeutics (NASDAQ:CRSP) Announces Earnings ResultsCRISPR Therapeutics (NASDAQ:CRSP - Get Free Report) announced its earnings results on Wednesday. The company reported ($1.43) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($1.35) by ($0.08). The firm had revenue of $0.50 million for the quarter, compared to the consensus estimate of $25.53 million. The business's revenue for the quarter was down 99.5% compared to the same quarter last year. During the same period in the previous year, the firm posted ($0.67) earnings per share.May 9, 2024 | marketbeat.comCRISPR Therapeutics (NASDAQ:CRSP) PT Lowered to $65.00 at Wells Fargo & CompanyWells Fargo & Company cut their price target on shares of CRISPR Therapeutics from $70.00 to $65.00 and set an "equal weight" rating for the company in a report on Thursday.May 9, 2024 | marketbeat.comCRISPR Therapeutics (NASDAQ:CRSP) Shares Down 1.7% on Disappointing EarningsCRISPR Therapeutics (NASDAQ:CRSP) Stock Price Down 1.7% After Earnings MissMay 9, 2024 | markets.businessinsider.comStrong Buy Rating for Crispr Therapeutics AG Amid Innovative Advances and Global ExpansionMay 9, 2024 | marketbeat.comCRISPR Therapeutics (NASDAQ:CRSP) Given New $52.00 Price Target at Robert W. BairdRobert W. Baird lifted their price target on shares of CRISPR Therapeutics from $46.00 to $52.00 and gave the company a "neutral" rating in a research note on Thursday.May 9, 2024 | globenewswire.comCRISPR Therapeutics to Present at the Bank of America Securities Health Care ConferenceMay 8, 2024 | investorplace.comCRSP Stock Earnings: CRISPR Therapeutics Misses EPS, Misses Revenue for Q1 2024May 8, 2024 | marketbeat.comCRISPR Therapeutics (NASDAQ:CRSP) Trading Down 3.1%CRISPR Therapeutics (NASDAQ:CRSP) Stock Price Down 3.1% Get CRISPR Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CRSP and its competitors with MarketBeat's FREE daily newsletter. Email Address Crypto Pioneer Says: “The last crypto bull market has begun.” (Ad)Right now, there’s over $6 trillion in potential investment money waiting on the sidelines. That means this crypto bull market has a lot more room to run before it comes close to being a bubble. Click here if you’d like to learn more about these five cryptos… CRSP Media Mentions By Week CRSP Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. CRSP News Sentiment▼0.200.42▲Average Medical News Sentiment CRSP News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. CRSP Articles This Week▼349▲CRSP Articles Average Week Get CRISPR Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CRSP and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: Krystal Biotech News Immunovant News Halozyme Therapeutics News ImmunityBio News Revolution Medicines News Exelixis News SpringWorks Therapeutics News Iovance Biotherapeutics News Denali Therapeutics News Immunocore News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:CRSP) was last updated on 5/20/2024 by MarketBeat.com Staff From Our PartnersShocking: One AI startup's revenue could surge 4,735%Manward PressThe Overlooked Retirement Asset You Probably Don’t OwnCrypto 101 MediaNext President (Not Trump. Not Biden.)The Freeport SocietyUrgent Nvidia WarningAltimetryElon’s New Device is About to Shock the WorldInvestorPlace"The Biggest Drug Ever" Is ComingBehind the MarketsCEO of Biggest AI Chipmaker Just Dropped a Bombshell…Banyan Hill PublishingExposed: 10 CENT Crypto to Explode May 20th?True Market Insiders Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding CRISPR Therapeutics AG Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
